Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

• Status: Completed
• Trial end date: 2004-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• Subjects with normal renal function: Subjects must be healthy with estimated creatinine clearance >80 mL/min

• Subjects with renal impairment: Subjects should be in good general health commensurate with the population with chronic kidney disease

Exclusion Criteria:

• Kidney transplant patients

• Subjects with any condition possibly affecting drug absorption

• Subjects with malignancies with the exception of adequately treated basal cell carcinoma of the skin